Oct 27 (Reuters) - Eli Lilly ( LLY ) expects to start

selling its weight-loss drug in Hong Kong as early as the end of

this year, Bloomberg News reported on Sunday.

The company has received the Hong Kong government approval

to sell its tirzepatide injections - branded as Mounjaro - in a

device called Kwikpen for both long-term weight management and

type 2 diabetes, Eli Lilly ( LLY ) told Bloomberg in a statement.

(Reporting by Jahnavi Nidumolu in Bengaluru)